Atossa Genetics, Inc. (NASDAQ:ATOS) Will Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016, Awaits Market Response to News

Clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, Atossa Genetics, Inc. (NASDAQ:ATOS), announces it will present at the Micro Main Event Conference.

SEATTLE, WA–(Marketwired – Dec 1, 2016) – Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.

Registered attendees may request meetings through the Meetmax system through the following link:

View Atossa Genetics’ Profile here:

About LD Micro

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenters. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at or visit for more information.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Original Source


Atossa Genetics, Inc. (NASDAQ:ATOS) shares have moved +6.12% on the news thus far today and have traded in the range of $1.85 – 2.15 during the current session. In order to take a look at where the stock might be headed longer term, investors often look to research firms that cover the stock. Sell-side research firms currently have a consensus one-year price target of $26.25 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  The sell-side analysts are projecting earnings per share of $0.00 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-2.57 per share according to First Call.

Are Shares of Atossa Genetics, Inc. (NASDAQ:ATOS) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where the stock is trading on a technical level, the stock is trading +17.68% away from its 50-day moving average of $1.77.  Based on the most recent available data, the equity is -80.47% off of its 52-week high of $10.65 and +38.60% away from its 52-week low which is $1.50.

Today, the stock opened at $1.92 and the last bid at the time of writing stood at $2.08.  During the session thus far, the equity dipped down to $1.85 and touched $2.15 as the high point.  Atossa Genetics, Inc. (NASDAQ:ATOS) has a market cap of $7.88M and has seen an average daily volume of 97,522 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment